Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A

Archives of Ophthalmology

Volumn 128, Issue 4, 2010, Pages 403-411

  Berson, Eliot L ^a   Rosner, Bernard ^a   Sandberg, Michael A ^a   Weigel DiFranco, Carol ^a   Brockhurst, Robert J ^a   Hayes, K C ^d   Johnson, Elizabeth J ^b   Anderson, Ellen J ^a   Johnson, Chris A ^e   Gaudio, Alexander R ^a   Willett, Walter C ^c   Schaefer, Ernst J ^b  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b TUFTS UNIVERSITY   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d BRANDEIS UNIVERSITY   (United States)

^e UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RETINOL PALMITATE; VISUAL PIGMENT; XANTHOPHYLL;

ADULT; ANALYZER; ARTICLE; BLOOD EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ELECTRORETINOGRAM; FEMALE; FOLLOW UP; GENETICS; HUMAN; MAJOR CLINICAL STUDY; MALE; OPTICAL DENSITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA LUTEA; RETINITIS PIGMENTOSA; SCORING SYSTEM; SIDE EFFECT; SMOKING; TABLET; TREATMENT DURATION; VISION; VISUAL FIELD; VISUAL IMPAIRMENT; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

ADOLESCENT; ADULT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUTEIN; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PERIMETRY; QUESTIONNAIRES; RETINITIS PIGMENTOSA; TABLETS; VISION DISORDERS; VISUAL ACUITY; VISUAL FIELDS; VITAMIN A; YOUNG ADULT;

EID: 77950795808     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2010.32     Document Type: Article

References (47)

1. Berson EL. Retinitis pigmentosa: the Friedenwald Lecture. Invest Ophthalmol Vis Sci. 1993;34(5):1659-1676.
2. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006;368(9549): 1795-1809.
3. Berson EL, Rosner B, Sandberg MA, et al. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol. 1993; 111(6):761-772. (Pubitemid 23170587)
4. Bone RA, Landrum JT, Tarsis SE. Preliminary identification of the human macular pigment. Vision Res. 1985;25(11):1531-1535.
5. Parker RS. Absorption, metabolism and transport of carotenoids. FASEB J. 1996; 10(5):542-551.
6. Clevidence BA, Bieri JG. Association of carotenoids with human plasma lipoproteins. Methods Enzymol. 1993;214:33-46. (Pubitemid 23150482)
7. Yemelyanov AY, Katz NB, Bernstein PS. Ligand-binding characterization of xanthophyll carotenoids to solubilized membrane proteins derived from human retina. Invest Ophthalmol Vis Sci. 2001;42(4):S359.
8. Snodderly DM, Brown PK, Delori FC, Auran JD. The macular pigment, I: absorbance spectra, localization, and discrimination from other yellow pigments in primate retinas. Invest Ophthalmol Vis Sci. 1984;25(6):660-673.
9. Snodderly DM, Auran JD, Delori FC. The macular pigment, II: spatial distribution in primate retinas. Invest Ophthalmol Vis Sci. 1984;25(6):674-685.
10. Sommerburg OG, Siems WG, Hurst JS, Lewis JW, Kliger DS, van Kuijk JGM. Lutein and zeaxanthin are associated with photoreceptors in the human retina. Curr Eye Res. 1999;19(6):491-495.
11. Rapp LM, Maple SS, Choi JH. Lutein and zeaxanthin concentrations in rod outer segment membranes from perifoveal and peripheral human retina. Invest Ophthalmol Vis Sci. 2000;41(5):1200-1209.
12. Handelman GJ, Dratz EA, Reay CC, van Kuijk FJGM. Carotenoids in the human macula and whole retina. Invest Ophthalmol Vis Sci. 1988;29(6):850-855.
13. Bone RA, Landrum JT, Friedes LM, et al. Distribution of lutein and zeaxanthin stereoisomers in the human retina. Exp Eye Res. 1997;64(2):211-218. (Pubitemid 27139567)
14. Gruber M, Chappell R, Millen A, et al. Correlates of serum lutein zeaxanthin: findings from the Third National Health and Nutrition Examination Survey. J Nutr. 2004;134(9):2387-2394. (Pubitemid 39201613)
15. Ham WT Jr. Ocular hazards of light sources: review of current knowledge. J Occup Med. 1983;25(2):101-103.
16. Khachik F, Bernstein PS, Garland PL. Identification of lutein and zeaxanthin oxidation products in human and monkey retinas. Invest Ophthalmol Vis Sci. 1997; 38(9):1802-1811. (Pubitemid 27382346)
17. Schalch W. Carotenoids in the retina: a review of their possible role in preventing or limiting damage caused by light and oxygen. In: Emerit I, Chase B, eds. Free Radicals and Aging. Basel, Switzerland: Birkhauser; 1992.
18. Brown L, Rimm EB, Seddon JM, et al. A prospective study of carotenoid intake and risk of cataract extraction in US men. Am J Clin Nutr. 1999;70(4):517-524. (Pubitemid 29463446)
19. Chasan-Taber L, Willett WC, Seddon JM, et al. A prospective study on vitamin supplement intake and cataract extraction among US women. Epidemiology. 1999; 10(6):679-684. (Pubitemid 29494047)
20. Seddon JM, Ajani UA, Sperduto RD, et al; Eye Disease Case-Control Study Group. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. JAMA. 1994;272(18):1413-1420.
21. Mohammedshah FY, Douglass JS, Amann MM, Heimbach JM. Dietary intakes of lutein and zeaxanthin and total carotenoids among Americans age 50 and above [abstract]. FASEB J. 1999;13:A554.
22. Nebeling LC, Forman MR, Graubard BI, Snyder RA. Changes in carotenoid intake in the United States: the 1987 and 1992 National Health Interview Surveys. J Am Diet Assoc. 1997;97(9):991-996.
23. Tucker KL, Chen H, Vogel S, Wilson PW, Schaefer EJ, Lammi-Keefe CJ. Carotenoid intakes, assessed by dietary questionnaire, are associated with plasma carotenoid concentrations in an elderly population. J Nutr. 1999;129(2):438-445. (Pubitemid 29072133)
24. VandenLangenberg GM, Brady WE, Nebeling LC, et al. Influence of using different sources of carotenoid data in epidemiologic studies. J Am Diet Assoc. 1996; 96(12):1271-1275. (Pubitemid 27381751)
25. Willett WC, Sampson L, Browne ML, et al. The use of a self-administered questionnaire to assess diet four years in the past. Am J Epidemiol. 1988;127(1): 188-199. (Pubitemid 18034380)
26. Neuringer M, Sandstrom MM, Johnson EJ, Snodderly DM. Nutritional manipulation of primate retinas, I: effects of lutein or zeaxanthin supplements on serum and macular pigment in xanthophyll-free rhesus monkeys. Invest Ophthalmol Vis Sci. 2004;45(9):3234-3243. (Pubitemid 39121861)
27. Broich CR, Gerber LE, Erdman JW Jr. Determination of lycopene, alpha- and betacarotene and retinyl esters in human serum by reversed-phase high performance liquid chromatography. Lipids. 1983;18(3):253-258.
28. Wooten BR, Hammond BR Jr, Land RI, Snodderly DM. A practical method for measuring macular pigment optical density. Invest Ophthalmol Vis Sci. 1999; 40(11):2481-2489.
29. Ferris FL III, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol. 1982;94(1):91-96. (Pubitemid 12080556)
30. Mills RP, Barnebey HS, Migliazzo CV, Li Y. Does saving time using FASTPAC or suprathreshold testing reduce quality of visual fields? Ophthalmology. 1994; 101(9):1596-1603. (Pubitemid 24347059)
31. Schaumberger M, Schafer B, Lachenmayr BJ. Glaucomatous visual fields: FASTPAC versus full threshold strategy of the Humphrey Field Analyzer. Invest Ophthalmol Vis Sci. 1995;36(7):1390-1397.
32. Flanagan JG, Moss ID, Wild JM, et al. Evaluation of FASTPAC: a new strategy for threshold estimation with the Humphrey Field Analyzer. Graefes Arch Clin Exp Ophthalmol. 1993;231(8):465-469.
33. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35(3):549-556.
34. Berson EL, Rosner B, Sandberg MA, et al. Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Arch Ophthalmol. 2004;122(9):1297-1305. (Pubitemid 39180849)
35. Aleman TS, Duncan JL, Bieber ML, et al. Macular pigment and lutein supplementation in retinitis pigmentosa and Usher syndrome. Invest Ophthalmol Vis Sci. 2001;42(8):1873-1881.
36. Johnson EJ, Chung H-Y, Caldarella SM, Snodderly DM. The influence of supplemental lutein and docosahexaenoic acid on serum, lipoproteins, and macular pigmentation. Am J Clin Nutr. 2008;87(5):1521-1529.
37. Diggle P, Heagerty P, Liang K-Y, Zeger S, eds. Analysis of Longitudinal Data. Oxford, England: Oxford University Press; 2002.
38. SAS [computer program]. Version 9.1.3. Cary, NC: SAS Institute, Inc; 2006.
39. Rosner B, Glynn RJ, Lee M-LT. Extension of the rank sum test for clustered data: two-group comparisons with group membership defined at the subunit level. Biometrics. 2006;62(4):1251-1259. (Pubitemid 44915547)
40. Stone CJ, Koo CY. Additive splines in statistics. In: Proceedings of the Statistical Computing Section of the American Statistical Association. Alexandria, VA: American Statistical Association; 1985:45-48.
41. Harrell FJ. Regression Modeling Strategies. New York, NY: Springer Publishing Co; 2001.
42. Berson EL, Rosner B, Sandberg MA, et al. Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses. Arch Ophthalmol. 2004;122(9):1306-1314. (Pubitemid 39180850)
43. Hammond BR Jr, Johnson EJ, Russell RM, et al. Dietary modification of human macular pigment density. Invest Ophthalmol Vis Sci. 1997;38(9):1795-1801.
44. Bahrami H, Melia M, Dagnelie G. Lutein supplementation in retinitis pigmentosa: PC-based vision assessment in a randomized double-masked placebocontrolled clinical trial [NCT00029289]. BMC Ophthalmol. 2006;6:23. (Pubitemid 44124839)
45. Satia JA, Littman A, Slatore CG, Galanko JA, White E. Long-term use of betacarotene, retinol, lycopene, and lutein supplements and lung cancer risk: results from the VITamins and Lifestyle (VITAL) Study. Am J Epidemiol. 2009;169 (7):815-828.
46. Feskanich D, Singh V, Willett WC, Colditz GA. Vitamin A intake and hip fractures among postmenopausal women. JAMA. 2002;287(1):47-54. (Pubitemid 34251675)
47. Michaëlsson K, Lithell H, Vessby B, Melhus H. Serum retinol levels and the risk of fracture. N Engl J Med. 2003;348(4):287-294. (Pubitemid 36119983)